Evidence map›Paper›PMID 29037516›Full record

Trial reportJoint bone spine2018

Statin use and knee osteoarthritis progression: Results from a post-hoc analysis of the SEKOIA trial.

Florent Eymard, Camille Parsons, Mark H Edwards, Florence Petit-Dop, Jean-Yves Reginster, Olivier Bruyère, Xavier Chevalier, Cyrus Cooper, Pascal Richette

Abstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Joint bone spine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Florent EymardDepartment of rheumatology, Henri-Mondor hospital, AP-HP, 94010 Créteil cedex, France.
Camille ParsonsMRC lifecourse epidemiology unit, Southampton general hospital, Southampton SO16 6YD, UK.
Mark H EdwardsMRC lifecourse epidemiology unit, Southampton general hospital, Southampton SO16 6YD, UK.
Florence Petit-DopInnovative pole of rheumatology, Servier, 92150 Suresnes, France.
Jean-Yves ReginsterDepartment of public health and health economics, university of Liege, 4020 Liege, Belgium.
Olivier BruyèreDepartment of public health and health economics, university of Liege, 4020 Liege, Belgium.
Xavier ChevalierDepartment of rheumatology, Henri-Mondor hospital, AP-HP, 94010 Créteil cedex, France.
Cyrus CooperMRC lifecourse epidemiology unit, Southampton general hospital, Southampton SO16 6YD, UK.
Pascal RichetteDepartment of rheumatology, Lariboisière hospital, AP-HP, 75475 Paris cedex 10, France; Inserm U1132, university Paris 7, Lariboisière hospital, AP-HP, 75475 Paris cedex 10, France. Electronic address: pascal.richette@aphp.fr.
MRC Lifecourse Epidemiology Unit · GBUniversité Paris-Est Créteil · FRUniversity of Liège · BEInserm · FRServier (France) · FR

Funding

Medical Research Council G0400491Medical Research Council MC_U147585819Medical Research Council MC_U147585824Medical Research Council MC_U147585827Medical Research Council MC_UP_A620_1014Medical Research Council MC_UU_12011/1
6 · The paper itself

Abstract

objectiveEpidemiological and experimental studies have suggested that lipid disorders might be involved in the pathophysiology of knee osteoarthritis (OA). Studies assessing the effect of statins on knee OA progression have shown conflicting results. We investigated the impact of statin use on radiological progression in patients with radiological and symptomatic knee OA.

methodsIn total, 336 patients from the placebo arm of SEKOIA trial completed the 3-year follow-up and were included in this post-hoc analysis. Statin use was recorded at baseline interview. Minimal medial tibiofemoral joint space was measured on plain radiographs by an automated method at baseline and then annually. Radiologic progression was defined as joint space narrowing≥0.5mm over 3 years.

resultsOverall, 71 patients were statin users (21.1%). They had a higher BMI (31.1±5.3 vs. 29.3±5.2kg/m

conclusionAmong patients with knee OA, statin use was associated with radiological worsening over 3 years, regardless of other potential confounding factors (obesity, type 2 diabetes, hypertension, disease duration, symptom intensity and radiological severity).

Indexed as

Disease ProgressionAgedAnalysis of VarianceDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleFollow-Up StudiesFranceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsInternationalityMaleMiddle AgedMultivariate AnalysisOsteoarthritis, KneeHydroxymethylglutaryl-CoA Reductase InhibitorsDyslipidemiaKnee osteoarthritisRadiological progressionStatin

Identifiers

PMID29037516
PMCPMC5858762
OpenAlexW2761050613

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.